Armistice Capital, LLC has filed its 13F form on February 14, 2025 for Q4 2024 where it was disclosed a total value porftolio of $7.08 Billion distributed in 232 stocks.
Among their holdings, we can observe that their the top five positions include companies like: Ptc Therapeutics, Inc. with a value of $288M, Supernus Pharmaceuticals, Inc. with a value of $175M, Travere Therapeutics, Inc. with a value of $128M, Neurocrine Biosciences Inc with a value of $122M, and Incyte Corp with a value of $122M.
Examining the 13F form we can see an increase of $1.06B in the current position value, from $6.02B to 7.08B .
Armistice Capital, LLC is based out at New York, NY
Below you can find more details about Armistice Capital, LLC portfolio as well as his latest detailed transactions.
Portfolio value
$7.08 Billion
$2.97 Billion
$2.74 Billion
$455 Million
$393 Million
$383 Million
$45.7 Million
$34.5 Million
$27.5 Million
$24.9 Million
Stock Market Cap.
Holding Value (Reported)
# of Shares.
Last Trade
Trade History
-
$0
0.0% of portfolio
-
Q4 2024
New
-
$0
0.0% of portfolio
-
Q4 2024
Added 409.33%
$0
$2,000
0.0% of portfolio
13,450
Q4 2024
Reduced 94.44%
-
$0
0.0% of portfolio
-
Q4 2024
New
$14.2M
$80,000
0.0% of portfolio
104,000
Q4 2024
Added 4.0%
-
$0
0.0% of portfolio
-
Q4 2024
New
Allurion Technologies Inc
-
$0
0.0% of portfolio
-
Q4 2024
Reduced 3.57%
-
$0
0.0% of portfolio
-
Q4 2024
Reduced 36.44%
-
$0
0.0% of portfolio
-
Q3 2024
Reduced 87.5%
$0
$0
0.0% of portfolio
188
Q4 2024
New
-
$0
0.0% of portfolio
-
Q4 2024
Added 158.48%
$0
$65,000
0.0% of portfolio
545,000
Q2 2023
Reduced -0.0%
-
$0
0.0% of portfolio
-
Q4 2024
New
-
$0
0.0% of portfolio
-
Q4 2024
Reduced 52.52%
-
$0
0.0% of portfolio
-
Q4 2024
Reduced 45.54%
-
$0
0.0% of portfolio
-
Q4 2024
Added 47.06%
$0
$85,000
0.0% of portfolio
715,000
Q2 2023
Reduced -0.0%
-
$0
0.0% of portfolio
-
Q4 2024
Added 39.42%
-
$0
0.0% of portfolio
-
Q2 2023
Reduced -0.0%
-
$0
0.0% of portfolio
-
Q4 2024
New
$0
$0
0.0% of portfolio
2,142
Q4 2024
New
-
$0
0.0% of portfolio
-
Q4 2024
New
-
$0
0.0% of portfolio
-
Q4 2024
New
-
$0
0.0% of portfolio
-
Q2 2023
Reduced -0.0%
-
$0
0.0% of portfolio
-
Q4 2024
New
-
$0
0.0% of portfolio
-
Q4 2024
Reduced 43.47%
-
$0
0.0% of portfolio
-
Q2 2023
Reduced -0.0%
-
$0
0.0% of portfolio
-
Q4 2024
Reduced 20.37%
-
$0
0.0% of portfolio
-
Q4 2024
Added 151.77%
-
$0
0.0% of portfolio
-
Q4 2024
New
$0
$0
0.0% of portfolio
1,334
Q4 2024
New
-
$0
0.0% of portfolio
-
Q4 2024
New
-
$0
0.0% of portfolio
-
Q4 2024
Reduced 14.08%
-
$0
0.0% of portfolio
-
Q4 2024
Added 122.5%
-
$0
0.0% of portfolio
-
Q2 2023
Reduced -0.0%
-
$0
0.0% of portfolio
-
Q4 2024
Added 9.51%
-
$0
0.0% of portfolio
-
Q4 2024
New
-
$0
0.0% of portfolio
-
Q1 2024
Reduced 95.0%
-
$0
0.0% of portfolio
-
Q4 2024
Added 32.85%
-
$0
0.0% of portfolio
-
Q4 2024
Reduced 68.85%
-
$0
0.0% of portfolio
-
Q4 2024
Added 353.82%
-
$0
0.0% of portfolio
-
Q2 2024
New
Ge Healthcare Technologies I
-
$0
0.0% of portfolio
-
Q4 2024
Added 108.73%
Intensity Therapeutics Inc
-
$0
0.0% of portfolio
-
Q4 2024
New
-
$0
0.0% of portfolio
-
Q2 2023
Reduced -0.0%
$0
$3,000
0.0% of portfolio
18,125
Q3 2024
Reduced 87.5%
-
$0
0.0% of portfolio
-
Q4 2024
Reduced 92.31%
-
$0
0.0% of portfolio
-
Q4 2024
New
-
$0
0.0% of portfolio
-
Q4 2024
Added 53.21%
-
$0
0.0% of portfolio
-
Q4 2024
Reduced 90.0%
